V

Vaxcyte

Develops broad-spectrum vaccines for bacterial infections

Director – Immunoassay Development

Full-Time
$213k - $250k+ Equity component
Expert
PhD
San Carlos, CA, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A PhD in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related field, or equivalent experience, with a minimum of 10 years of experience; other combinations of education and/or experience may be considered.
  • Demonstrated scientific depth, independent immunoassay development leadership, complex troubleshooting experience, and ability to lead cross-functional technical workstreams.
  • Significant hands-on, lab-based experience developing, optimizing, troubleshooting, transferring, validating, lifecycle-managing, and executing immunoassays in vaccine CMC, biologics analytical development, QC, ASAT, or other regulated analytical environments.
  • Demonstrated expertise in immunoassay method development, including assay format selection, reagent strategy, sample preparation, assay optimization, robustness assessment, qualification, validation readiness, method transfer, and lifecycle management.
  • Strong technical experience with ligand-binding immunoassay platforms such as ELISA, MSD, or other relevant immunoassay technologies.
  • Proven ability to troubleshoot complex immunoassay performance trends using structured, data-driven root-cause analysis approaches.
  • Experience evaluating alternative or innovative immunoassay platforms and translating platform learnings into fit-for-purpose analytical strategies.
  • Experience developing or improving potency, antigenicity, identity, or impurity assays supporting vaccine or biologics release, stability, comparability, process development, method transfer, validation, routine testing, or regulatory submissions.
  • Experience overseeing outsourced immunoassay activities, including CRO, CDMO, contract testing laboratory, reagent vendor, or external technology partner interactions.
  • Demonstrated ability to manage daily laboratory operations, including study planning, staff planning, sample and reagent readiness, testing prioritization, data review, documentation, and technical support.
  • Strong working knowledge of global regulatory expectations for analytical methods supporting vaccines and biologics, including FDA, EMA, ICH, and GMP expectations.
  • Solid understanding of protein chemistry, polysaccharide chemistry, conjugation chemistry, antigen structure, antibody-antigen interactions, and biological sample matrix effects as applied to vaccine analytical development.
  • Demonstrated experience leading, mentoring, and developing laboratory scientists, including building team capability, setting priorities, managing performance, providing technical coaching, and fostering a collaborative culture.
  • Proven ability to manage multiple technical workstreams, outsourced activities, validation-support activities, routine testing needs, resources, timelines, and deliverables in a fast-paced, matrixed environment.
  • Strong scientific judgment and the ability to make sound technical recommendations when working with incomplete, complex, or conflicting data.
  • Excellent written and verbal communication skills, with the ability to clearly communicate complex technical concepts to cross-functional stakeholders, senior leaders, external partners, and regulatory audiences.
  • Strong commitment to data integrity, documentation quality, scientific excellence, accountability, and continuous improvement.
Responsibilities
  • Help establish, lead, and scale the Immunoassay capability within the CMC Immunoassay group, including defining scope, operating model, technical standards, platform strategy, outsourcing approach, validation support model, routine testing model, and control strategy priorities aligned with CMC and program needs.
  • Provide daily laboratory leadership, including experimental planning, laboratory schedule coordination, study prioritization, reagent and sample readiness, data review, documentation expectations, instrument and workflow oversight, and hands-on technical support to ensure high-quality execution.
  • Build, mentor, and manage a laboratory-based team of scientists responsible for immunoassay development, optimization, troubleshooting, qualification support, method transfer, validation support, routine analytical testing, lifecycle management, and continuous improvement.
  • Strengthen Vaxcyte’s immunoassay portfolio by developing fit-for-purpose immunoassays that support potency, antigenicity, identity, impurity, characterization, comparability, release, stability, and lifecycle needs across the vaccine pipeline.
  • Provide hands-on scientific leadership for assay design, sample preparation strategy, reagent strategy, plate or bead format selection, signal detection approach, data analysis model, system suitability expectations, and robustness assessment.
  • Lead structured immunoassay troubleshooting and root-cause analysis for assay variability, reagent performance, sample preparation, matrix effects, antigen accessibility, signal response, curve behavior, recovery, precision, specificity, robustness, and long-term method trending.
  • Evaluate and implement innovative or alternative immunoassay technologies, including ELISA, MSD, automation-enabled workflows, and other relevant ligand-binding assay formats.
  • Develop new immunoassay methods from concept through optimization, qualification readiness, transfer readiness, validation readiness, and lifecycle strategy, including control strategy considerations and documentation suitable for CMC decision-making.
  • Strengthen immunoassay analytical control strategies, including critical reagent strategy, reference material strategy, assay controls, system suitability, sample preparation, acceptance criteria, bridging approaches, trending, stability planning, and lifecycle monitoring.
  • Oversee outsourced immunoassay activities with CROs, CDMOs, contract testing laboratories, reagent vendors, and external technology partners, including technical scope definition, study design review, data review, vendor performance oversight, and deliverable acceptance.
  • Support immunoassay method validation activities in partnership with ASAT, QC, Quality, Regulatory, and external testing partners, including validation strategy, protocol input, acceptance criteria, data interpretation, deviation support, and final report review.
  • Support routine immunoassay testing needs within the CMC Immunoassay group, including development-stage testing, characterization testing, platform evaluation studies, method bridging, comparability support, reagent qualification, and other non-GMP or GMP-supporting analytical activities.
  • Support QC and ASAT teams in technical questions related to release, stability, comparability, PPQ, method transfer, validation readiness, and commercial readiness activities.
  • Develop phase-appropriate immunoassay strategies across the vaccine pipeline, ensuring methods and control strategies are aligned with preclinical, clinical, late-stage, BLA, commercial, and lifecycle needs.
  • Manage immunoassay development, outsourcing, validation-support, routine testing, and platform innovation activities across multiple projects, including resource planning, timeline management, deliverable tracking, and risk escalation.
  • Establish a high-performing laboratory culture grounded in scientific rigor, accountability, collaboration, transparency, data integrity, hands-on problem solving, operational discipline, and continuous learning.
  • Contribute to regulatory submissions, health authority responses, technical reports, method development reports, validation strategies, comparability packages, platform evaluation summaries, and BLA-supporting documentation.
  • Represent Immunoassay Development in technical governance forums, program teams, cross-functional reviews, vendor discussions, and external collaborations as needed.
Desired Qualifications
  • Hands-on experience with MSD platforms.
  • Experience working in or supporting GMP-regulated analytical environments, including familiarity with method qualification, validation, transfer, change control, deviations, investigations, CAPA, data integrity, and lifecycle management.
  • Direct experience with conjugated vaccines, polysaccharide-protein conjugates, multivalent vaccines, or other complex biologics.
  • Experience supporting late-stage development, PPQ readiness, BLA preparation, commercial launch, or lifecycle management of vaccine or biologics programs.
  • Direct experience supporting analytical methods used for GMP release and stability testing.
  • Experience with immunoassay transfer, validation, bridging, comparability, critical reagent qualification, reference material qualification, and long-term method performance monitoring.
  • Experience managing outsourced immunoassay development, validation, platform evaluation, or routine testing activities with external laboratories or technology partners.
  • Experience developing alternative or next-generation immunoassay methods to strengthen analytical capability and support long-term control strategy.
  • Experience interacting with global health authorities on analytical, potency, antigenicity, or immunoassay-related topics.
  • Experience building or scaling analytical capabilities or laboratory teams within a growing organization.
  • Experience with automation, high-throughput immunoassay workflows, multiplex assay design, LIMS, ELN, and digital data analysis tools.
  • Experience with multivalent or highly complex vaccine programs.

About the company

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

0%
BBNS
Oct 7th, 2026
Biotech stocks to consider - october 5th.

Biotech stocks to consider - october 5th. Moderna, Vaxcyte, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies involved in developing and commercializing biotechnology products, such as pharmaceuticals, medical devices, diagnostics, and gene or cell therapies. For investors, these stocks can offer significant growth potential but often carry elevated risks due to clinical-trial outcomes, regulatory decisions, high research costs, and uncertain profitability. These companies had the highest dollar trading volume of any Biotech stocks within the last several days. Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Discover more Shop Handbags View Collections Discover Luxury Vaxcyte (PCVX). Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. Amgen (AMGN). Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Yahoo Finance
Oct 6th, 2026
Vaxcyte's VAX-31 vaccine matches Pfizer's $6.49B Prevnar on all serotypes in Phase 3 trial

Vaxcyte announced its 31-valent pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial with 4,047 participants. The vaccine matched Pfizer's Prevnar 20 on all 20 shared serotypes and Merck's Capvaxive on 17 of 19 shared serotypes. Pfizer's Prevnar franchise generated $6.49 billion in 2025, representing roughly 10% of the company's $62.58 billion total revenue. The franchise grew just 1% last year, with Pfizer citing lower US market share. Merck's Capvaxive brought in $759 million in 2025, about 1% of its revenue. Pfizer trades at 9.87x forward earnings whilst Merck trades at 16.36x. Vaxcyte plans to file for approval in the first half of 2028. The company expects results from two additional trials in the first half of 2027.

Minyanville
Oct 5th, 2026
Vaxcyte launches dual $500M offerings of stock and convertible notes due 2032

Vaxcyte, a clinical-stage vaccine innovation company, has commenced underwritten public offerings of $500 million in common stock and pre-funded warrants, alongside $500 million in convertible senior notes due 2032. The company intends to grant underwriters a 30-day option to purchase an additional $75 million in each offering to cover over-allotments. The offerings are not contingent on each other and remain subject to market conditions. Jefferies, Leerink Partners, BofA Securities, and others are serving as joint book-running managers. Vaxcyte plans to use proceeds to fund clinical development of its VAX-31 adult and paediatric programmes, manufacturing scale-up, commercial investments for anticipated US launch, and research into early-stage pipeline vaccine candidates. The notes will accrue interest payable semi-annually and mature on 15 October 2032.

Yahoo Finance
Oct 5th, 2026
Vaxcyte soars 50% as pneumococcal vaccine beats Pfizer and Merck in late-stage trial

Vaxcyte's experimental pneumococcal vaccine VAX-31 met all main efficacy objectives in its first late-stage trial, sending shares soaring 50% and pushing the company's market value past $12 billion. The vaccine matched Pfizer's Prevnar 20 and Merck's Capvaxive in protecting against 28 bacterial strains and proved superior against three unique strains in adults aged 50 and older. VAX-31 was inferior on two strains using a stricter statistical threshold, though analysts called this a "near best-case scenario." Vaxcyte's shot targets the pneumococcal vaccine market worth $8 billion annually, dominated by Pfizer's franchise which earned over $6 billion last year. VAX-31 covers more than 30 strains, offering broader protection than existing vaccines. The company will report results from two additional late-stage trials next year before seeking regulatory approval.

STAT
Oct 5th, 2026
Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market.

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market. Biotech company's pneumococcal vaccine hit primary endpoints in late-stage study. Oct. 5, 2026 General Assignment Reporter Vaxcyte said Monday that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the California-based biotech to compete with Pfizer and Merck. Vaxcyte's shot, VAX-31, is designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer's Prevnar and 21 strains for Merck's Capvaxive. In the trial, just over 3,500 adults age 50 and older were randomized to receive VAX-31, Prevnar, or Capvaxive. Investigators then measured the strength of their antibody responses against different strains.